Dedicated to developing and commercializing treatments for high-quality weight loss, breast cancer, and viral related ARDS

Changing the Paradigm for High-Quality Weight Loss

Veru is focused on the development of its novel, oral, selective androgen receptor modulator, also known as a SARM, to address one of the most significant medical needs, the loss of muscle, in patients undergoing weight loss therapy with Glucagon-like peptide-1 (GLP-1) drugs.

“We want to be there for patients undergoing GLP-1 therapy for weight loss to avoid the side effect of muscle loss while also furthering high-quality weight loss. Our goal is to make the weight loss process as healthy as it can be, ultimately benefiting patients and making their lives better. We are extremely excited to advance enobosarm to address this major health problem.”

— Dr. Mitchell Steiner, Veru’s Chief Executive Officer